ArticleCells2026
Immune Modulation in Peripheral Blood of Cystic Fibrosis Patients Following Ex Vivo Co-Culture with Mesenchymal Stem Cells.
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCystic fibrosis (CF) is an inherited multisystemic disease. Despite advances in treatment, many patients still experience progressive lung dysfunction. Dental follicle-derived mesenchymal stem cells (DF-MSCs) possess significant immunomodulatory potential in inflammatory airway diseases. We evaluated the effects of DF-MSCs on lymphocyte proliferation, CD4
methodsPBMCs from 20 CF patients and 20 matched healthy controls were isolated by density gradient centrifugation, stimulated with a CD3/CD28 T-cell-activating antibody cocktail (CD-mix), and co-cultured ex vivo with cryopreserved DF-MSCs. Lymphocyte proliferation was assessed by carboxyfluorescein succinimidyl ester (CFSE)-based flow cytometry, and Tregs were analyzed by flow cytometry. Cytokine levels in culture supernatants were quantified using a multiplex immunoassay.
resultsDF-MSC co-culture significantly suppressed lymphocyte proliferation in CF PBMCs. Treg frequency significantly increased in the stimulated CF samples following MSC co-culture. Following co-culture, levels of tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), and IL-23 decreased. In CF samples, levels of interferon-alpha 2 (IFN-α2), monocyte chemotactic protein-1 (MCP-1), interleukin-12 (IL-12), interleukin-18 (IL-18), and interleukin-33 (IL-33) were elevated.
conclusionsDF-MSCs reduced lymphocyte proliferation, increased Treg frequency, and regulated cytokine levels in CF, supporting their potential to restore immune balance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.